|
PROPETAMPHOS (SAFROTIN)
| Method number: | PV2050 |
| |
| Matrix: | Air |
| |
| Target Concentration: |
0.2 mg/m3 (arbitrary). There is no OSHA PEL or ACGIH TLV for propetamphos. |
| |
| Procedure: | Samples are collected
by drawing known volumes of air through 37-mm glass fiber filters
(GFFs). Samples are extracted with toluene and analyzed by gas
chromatography (GC) using an electron capture detector (ECD). |
| |
Recommended air volume and sampling rate: |
60 L at 1.0 L/min |
| |
| Detection limit of the overall procedure (based on
the recommended air volume and the analytical detection limit): |
0.02 mg/m3 |
| |
| Status of method: | Stopgap method.
This method has been partially evaluated and is presented for
information and trial use only. |
| |
| Date: January 1989 |
Chemist: Yogi Shah |
Carcinogen And Pesticide Branch
OSHA Analytical Laboratory
Salt Lake City, Utah
1. General Discussion
1.1. Background
1.1.1. History of procedure
This evaluation was undertaken to determine the effectiveness of a GFF as a sampling media for propetamphos.
1.1.2. Toxic effects (This section is for information only and should not be taken as the basis of OSHA policy).
The following paragraph is excerpted from the book OCCUPATIONAL DISEASES, A Guide To Their Recognition. Ref. 5.1.)
The organic phosphorus compounds act as irreversible inhibitors of
cholinesterase, thereby allowing the accumulation of large amounts of
acetylcholine. When a critical level of cholinesterase depletion is
reached, usually about 20% of normal, symptoms and signs of acetylcholine
accumulation poisoning become manifest. Symptoms may include
blurred vision, weakness, nausea, headache, abdominal cramps, chest
discomfort and diarrhea. Signs may include miosis, muscle twitching,
salivation, sweating, tearing, cyanosis, convulsions and coma. (Ref. 5.1.)
Besides being absorbed following inhalation or ingestion, organophosphorus
pesticides are readily absorbed through the intact skin (Ref. 5.1.).
When a particular pesticide has a low dermal LD50, a
skin notation should be added to the TLV or PEL.
Propetamphos has an acute oral LD50 of 119 mg/kg for male rats and an
acute dermal LD50 of 2300 mg/kg for male rats. (Ref. 5.2.)
By comparison with other organophosphorus insecticide 0.2 mg/m3,
without a skin notation, was used in this evaluation.
1.1.3. Potential workplace exposure
No estimate of worker exposure to propetamphos could be found. Propetamphos is used as an insecticide. (Ref.5.2)
1.1.4. Physical properties (Ref. 5-2.-5.4.)
| Molecular weight: |
281.31 |
| Molecular formula: | C10H20NO4PS |
| CAS #: | 31218-83-4 |
| Boiling point: | 87-89°C |
| Appearance: | yellowish oily liquid |
| Solubility: | practically insoluble in water soluble in most organic
solvents |
| Synonyms: | Safrotin, SAN 52139 I, Vel4283 |
| Chemical name: | (E)0-2-isopropoxy-carbonyl-l-methyl vinyl 0-methyl
ethylphosphoramido thioatc |
| Structure: |  |
1.2. Limit defining parameters
The detection limit of the analytical procedure is 0.013 ng per injection
This is the amount of analyte which will give a peak whose height is
approximately five times the baseline noise. This detection limit takes
into account a split ratio of 32 to 1 used in the capillary GC.
2. Sampling Procedure
2.1. Apparatus
2.1.1. A personal sampling pump that can be calibrated to within ± 5%
of the recommended flow rate with the sampling device in line.
2.1.2. A Glass Fiber Filter, 37-mm diameter, Gelman type A or equivalent.
2.1.3. A Cassette filter holder for 37-mm filter, Millipore M000037A0
or equivalent.(see figure 1.)
2.2. Reagents
No sampling reagents are required.
2.3. Sampling technique
2.3.1. Immediately before sampling remove the plastic plugs from the
cassette.
2.3.2. Attach the cassette to the sampling pump with flexible tubing.
2.3.3. Attach the cassette vertically in the employee's breathing zone
in such a manner that it does not impede work performance.
2.3.4. After sampling for the appropriate time, remove the cassette and
seal with plastic plugs.
2.3.5. Wrap each cassette end-to-end with an OSHA seal (Form 21).
2.3.6. Record the air volume for each sample, and list any possible
interferences.
2.3.7. Submit at least one blank for each set of sample. Handle the
blank in the same manner as the sample, except no air is drawn through
it.
2.3.8. Submit bulk samples for analysis in a separate container. Do not
ship with Air sample.
2.4. Extraction efficiency
Three GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL solution of
propetamphos in toluene. They were then extracted with 3.0 mL of toluene
and analyzed as in Section 3. The average recovery was 95.2%.
Table 2.4. Extraction Study
|
| Vial # | Amount spiked | Amount recovered | % Recovery |
|
| EX 1 | 14.10 µg | 13.76 µg | 97.6 |
| EX 2 | 14.10 µg | 12.83 µg | 91.0 |
| EX 3 | 14.10 µg | 13.66 µg | 96.9 |
| EX 4 | 0.00 µg | 0.00 µg | Blank |
|
2.5. Retention efficiency
Six GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL solution
of propetamphos in toluene. After overnight storage in a drawer at room
tempreture, 60 liters of humid air were drawn through each GFF. Three
of these GFFs, along with a blank GFF, werc then extracted and analyzed
as in Section 3. The average recovery was 90.3%. The remaining three
spiked GFFs were used in the storage study.
Table 2.5. Retention Efficiency Study
|
| Sample # | Amount spiked | Amount recovered | % Recovery |
|
| RET 1 | 14.10 µg | 13.30 µg | 94.4 |
| RET 2 | 14.10 µg | 12.60 µg | 89.4 |
| RET 3 | 14.10 µg | 12.29 µg | 87.1 |
| RET 4 | 0.00 µg | 0.00 µg | Blank |
|
2.6. Sample storage
The remaining three spiked GFFs from Section 2.5. (and a blank GFF) were
stored for 8 days in a drawer at room temperature. They were then
extracted and analyzed as in Section 3. The average recovery was 90.4%.
Table 2.6. Storage Study
|
| Sample # | Amount spiked | Amount recovered | % Recovery |
|
| ST 1 | 14.10 µg | 13.10 µg | 93.6 |
| ST 2 | 14.10 µg | 12.65 µg | 89.7 |
| ST 3 | 14.10 µg | 12.39 µg | 87.9 |
| ST 4 | 0.00 µg | 0.00 µg | Blank |
|
2.7. Recommended air volume and sampling rate
2.7.1. The recommended air volume is 60 L.
2.7.2. The recommended flow rate is 1.0 L/min.
2.8. Interferences (sampling)
It is not known if any compounds will interfere with the collection of
propetamphos. Suspected interferences should be reported to the
laboratory with submitted samples.
2.9. Safety precautions (sampling)
2.9.1. Attach the sampling equipment in such a manner that it will not
interfere with work performance or employee safety.
2.9.2. Follow all safety practices that apply to the work area being
sampled.
3. Analytical Procedure
3.1. Apparatus
3.1.1. A GC with an ECD. A Hewlett-Packard 5890A GC (capillary)
equipped with both an ECD and a Hewlett-Packard 7673A automatic
sampler was used in this evaluation.
3.1.2. A GC column capable of resolving propetamphos from any interferences.
A 60 m x 0.32 mm i.d. SE-30 GC capillary column, 0.25 µm thick film,
was used in this evaluation and is available from Supelco, Inc.,
Bellefonte, PA.
3.1.3. An electronic integrator or other suitable means of measuring
detector response. A Hewlett-Packard 3392A Integrator and a
Hewlett-Packard 3357 data system were used in this evaluation.
3.1.4. Vials, 4-mL and 2-mL glass with PTFE-lined septa.
3.1.5. Volumetric flasks, pipets, and syringes.
3.2. Reagents
3.2.1. Hydrogen, air, and nitrogen, GC grade.
3.2.2. Toluene, Pesticide grade.
3.2.3. Propetamphos. A 38.6% (w/w) solution in 1,3,5 trimethyl-benzene
from the EPA was used in this evaluation.
3.3. Standard preparation
Prepare stock standards by adding toluene to preweighed amounts of
propetamphos. Prepare working range standards by diluting stock
solutions with toluene. Store stock and dilute standards in a freezer.
3.4. Sample preparation
3.4.1. Transfer the 37-mm glass fiber filter to a 4-mL vial.
3.4.2. Add 3.0 ml. of toluene to each vial.
3.4.3. Seal the vials with Polytetrafluroethlene (PTFE) lined septa.
Allow them to extract for one hour periodically shaking by hand .
3.4.4. If necessary, transfer aliquots of the samples to the vials used in
GC analysis. In this evaluation the samples were transferred to 2-mL
glass vials, sealed with PTFE lined septa, and loaded on the automatic
sampler.
3.5. Analysis
3.5.1. Analytical conditions
| GC conditions |
|
| GC column: | 60 m x 0.32 mm i.d. SE-30, 0.25 µm |
| thick film |
| Column temperature: | 220°C (isothermal) |
| Carrier gas: | Hydrogen |
| Flow rate: | 1.97 mL/min |
| Split ratio: | 32 to 1 |
| Retention time: | 3.47 min |
| Injector conditions | |
| Temperature: | 230°C |
| Volume: | 1 µL |
| ECD conditions | |
| Air flow rate: | 100 mL./min |
| Auxiliary gas: | Nitrogen |
| Flow rate: | 20 mL/min |
| Temperature: | 300°C |
3.5.2. Chromatogram (See Figure 2.)
3.6. Interferences (analytical)
3.6.1. Any compound having a retention time similar to that of the analyte
is a potential interference. Generally, chromatographic conditions can
be altered to separate interferences from the analyte.
3.6.2. Retention time on a single column is not proof of chemical identity.
Analysis by an alternate GC column, flame photometric detector (FPD) and
confirmation by mass spectrometry are additional means of identification.
3.7. Calculations
3.7.1. Construct a calibration curve by plotting detector response versus
standard concentration.
3.7.2. Determine the concentration of propetamphos in samples and blank
from the calibration curve. If propetamphos is found in the blank make
a blank correction.
3.7.3. Determine the air concentration by the following formula.
| mg/m3 = |
(µg/mL in sample) × (extraction volume, mL) (air volume, L) × (extraction efficiency, decimal) |
3.8. Safety precautions (analytical)
3.8.1. Avoid exposure to all standards.
3.8.2. Avoid exposure to all solvents.
3.8.3. Wear safety glasses at all times.
4. Recommendations for Further Study
4.1. An OSHA Versatile Sampler (OVS-2) packed with XAD-2 adsorbent should
be evaluated as a sampling device for propetamphos.
4.2. A fully validated method should be developed.
Figure 1. Sampling Device
Figure 2. Chrbmatogram of propetamphos
5. References
5.1. "OCCUPATIONAL DISEASES, A Guide to their Recognition"; U.S.
Department of Health, Education, and Welfare; Public Health Service,
Public Health Service Publication No. 1097, U.S. Government Printing
Office; Washington, D.C., 1964; p 245.
5.2. "Farm Chemicals Handbook"; Meister Publishing Co.; Willoughby, OH, 1985; p C195.
5.3. Windholz, M., Ed.; "Merck Index", 10th ed.; Merck and Co.; Rahway, NJ, 1983; p 1126.
5.4. Registry of Toxic Effects of Chemical Substances, 1978 Edition.
(Lewis, R.J. and Tatken, R.L., Eds.) U.S. Department of Health,
Education and Welfare, Public Health Services, Center for Disease Control, National Institute for Occupational Safety and Health,
U.S. Government Printing Office, Washington, D.C.(1978).
|